U.S. Pharma Industry Analysis

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 07 Jul 2026	US$2.6t	US$425.2b	US$65.8b	15.3x	39.6x	6.1x
Thu, 04 Jun 2026	US$2.3t	US$424.1b	US$66.3b	15x	34.8x	5.4x
Sat, 02 May 2026	US$2.2t	US$416.3b	US$62.4b	17x	35.8x	5.4x
Mon, 30 Mar 2026	US$2.2t	US$405.9b	US$71.7b	16.7x	30.7x	5.4x
Wed, 25 Feb 2026	US$2.4t	US$411.7b	US$73.6b	18.9x	32.8x	5.9x
Fri, 23 Jan 2026	US$2.3t	US$404.6b	US$73.2b	19.6x	31.5x	5.7x
Sun, 21 Dec 2025	US$2.2t	US$402.8b	US$71.4b	19.8x	31.3x	5.5x
Tue, 18 Nov 2025	US$2.1t	US$402.7b	US$71.5b	19.1x	29.5x	5.2x
Thu, 16 Oct 2025	US$1.9t	US$389.2b	US$63.5b	18.3x	29.4x	4.8x
Sat, 13 Sep 2025	US$1.8t	US$387.9b	US$60.9b	18.9x	29.6x	4.6x
Mon, 11 Aug 2025	US$1.6t	US$387.9b	US$60.7b	18.4x	27x	4.2x
Wed, 09 Jul 2025	US$1.7t	US$382.7b	US$61.3b	18x	28.3x	4.5x
Fri, 06 Jun 2025	US$1.7t	US$382.7b	US$61.2b	17.9x	27.9x	4.5x
Sun, 04 May 2025	US$1.8t	US$382.7b	US$63.7b	17.2x	27.8x	4.6x
Tue, 01 Apr 2025	US$1.8t	US$380.6b	US$41.3b	15.9x	44.7x	4.9x
Thu, 27 Feb 2025	US$1.9t	US$381.2b	US$39.3b	17.3x	49.4x	5.1x
Sat, 25 Jan 2025	US$1.8t	US$370.4b	US$30.5b	18.4x	58.7x	4.8x
Mon, 23 Dec 2024	US$1.8t	US$369.4b	US$31.1b	16.7x	57.2x	4.8x
Wed, 20 Nov 2024	US$1.8t	US$373.8b	US$30.6b	19.9x	58x	4.7x
Fri, 18 Oct 2024	US$2.0t	US$365.3b	US$23.7b	18.7x	86x	5.6x
Sun, 15 Sep 2024	US$2.0t	US$364.3b	US$25.4b	18.8x	80.2x	5.6x
Tue, 13 Aug 2024	US$2.0t	US$362.1b	US$22.0b	16.5x	89.6x	5.4x
Thu, 11 Jul 2024	US$2.0t	US$357.6b	US$13.8b	15.4x	143.2x	5.5x
Sat, 08 Jun 2024	US$1.9t	US$358.3b	US$14.1b	15.6x	135.8x	5.3x
Mon, 06 May 2024	US$1.8t	US$358.0b	US$13.8b	21.4x	131.1x	5.1x
Wed, 03 Apr 2024	US$1.9t	US$355.2b	US$22.7b	24.1x	83.1x	5.3x
Fri, 01 Mar 2024	US$1.9t	US$355.2b	US$22.3b	23.7x	84.7x	5.3x
Sun, 28 Jan 2024	US$1.8t	US$375.2b	US$33.9b	24.6x	52.1x	4.7x
Tue, 26 Dec 2023	US$1.7t	US$375.1b	US$33.9b	32x	49.3x	4.4x
Thu, 23 Nov 2023	US$1.6t	US$375.1b	US$33.9b	26x	48.3x	4.4x
Sat, 21 Oct 2023	US$1.7t	US$382.7b	US$44.7b	17.6x	37x	4.3x
Mon, 18 Sep 2023	US$1.7t	US$381.8b	US$43.9b	18x	39.2x	4.5x
Wed, 16 Aug 2023	US$1.8t	US$381.7b	US$44.0b	19.1x	40.4x	4.7x
Fri, 14 Jul 2023	US$1.6t	US$392.8b	US$60.2b	17.9x	27.4x	4.2x

Current Industry PE

Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 39.6x which is lower than its 3-year average PE of 54.3x.

The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 6.1x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have grown 3.0% per year over the last three years.
Revenues for these companies have grown 2.7% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?


US Market	0.79%
Healthcare	0.97%
Pharma	-1.31%
Pharma	-1.31%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
TEVA Teva Pharmaceutical Industries	US$35.29	5.9% +US$2.3b	109.4%	PE26.3x
JNJ Johnson & Johnson	US$259.33	0.3% +US$2.0b	67.0%	PE29.7x
ZTS Zoetis	US$75.42	3.0% +US$909.7m	-52.0%	PE11.8x
VTRS Viatris	US$16.80	3.5% +US$663.8m	82.6%	PS1.3x
CRNX Crinetics Pharmaceuticals	US$42.03	13.8% +US$536.7m	44.6%	PS245.3x

Agomab Therapeutics NV Announces Design Of NOV-ERA Phase 2b Study With Ontunisertib In Fibrostenosing Crohn’s Disease

Agomab Therapeutics NV announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-ß RI) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD). Approximately 46% of Crohn’s disease patients have FSCD, or fibrotic strictures in the intestinal tract, which can cause obstructive symptoms leading to dietary change, malnutrition and surgery. Despite the large unmet medical need, there are no approved pharmacological therapies for FSCD. The Company has aligned with the FDA on the study design of NOV-ERA, including the study’s primary efficacy endpoint of endoscopic passability at Week 24 as assessed by the SES-CD narrowing score, as well as several secondary efficacy endpoints relevant to patients with FSCD. The protocol has been submitted to the FDA and has cleared central Institutional Review Board (IRB) approval in the U.S. In addition, the study has received approval by Health Canada. The Company has also submitted Clinical Trial Applications in multiple countries globally, including in the European Union and Asia Pacific territories. The Company expects to initiate the NOV-ERA study following receipt of applicable regulatory and ethics approvals and plans to dose the first participants in the second half of 2026. The planned NOV-ERA study is a randomized, double-blind, placebo-controlled, dose-ranging, multicenter Phase 2b trial to assess the efficacy and safety of ontunisertib in participants diagnosed with symptomatic FSCD. The trial is expected to enroll up to 320 adult patients globally. To be eligible for the trial, participants must have at least one naive or anastomotic endoscopically non-passable ileal stricture, confirmed by a centrally read Simple Endoscopic Score for Crohn’s Disease (SES-CD). Upon study initiation, participants will be randomized in a 1:1:1:1 ratio to receive either ontunisertib at one of three dose levels (400 mg, 200 mg, and 100 mg), or a matching placebo, administered twice daily. The trial will consist of a 6-week screening period, a 52-week treatment period, and a 2-week follow-up period. The primary endpoint is the proportion of patients achieving endoscopic passability of the ileal index stricture at Week 24. Key secondary efficacy endpoints include: Proportion of participants achieving endoscopic passability of the ileal index stricture at Week 52. Change from baseline in Magnetic Resonance Enterography (MRE) imaging features of the index stricture at Week 24 and Week 52. Change from baseline in total SES-CD at Week 24 and Week 52. Proportion of participants with an endoscopic response and remission at Week 24 and Week 52 compared to baseline. Change from baseline in Patient-Reported Outcome questionnaire for stricturing Crohn’s disease (S-PRO 2.0) severity score at Week 24 and Week 52. Time to an FSCD-related event (including surgery and endoscopic balloon dilation). The endpoints assessed in the NOV-ERA study are designed to inform the selection of potential registrational endpoints for ontunisertib in FSCD. Ontunisertib is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established. Ontunisertib (AGMB-129) is an oral small molecule GI-restricted inhibitor of ALK5 (or TGF-ß RI) currently in clinical development for the treatment of Fibrostenosing Crohn’s Disease (FSCD). TGF-ß is a major driver of fibrosis. Ontunisertib is specifically designed to inhibit ALK5/TGF-ß in the GI-tract. Rapid first-pass metabolism in the liver prevents clinically relevant systemic exposure, potentially delivering an improved safety profile over systemically available inhibitors in this class. Ontunisertib has received U.S. FDA Fast Track Designation. Crohn’s disease is a chronic progressive disease of the gastrointestinal tract. It is estimated that approximately 46% of patients with Crohn’s disease have fibrosis of the gastrointestinal tract, resulting in stricture formation and intestinal obstructions, most frequently in the terminal ileum. These strictures can cause obstructive symptoms leading to dietary change, malnutrition and surgery. Despite the large unmet medical need, there are no approved pharmacological therapies for FSCD.

U.S. Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Price target decreased by 7.2% to US$116

Merck Reports Positive Tulisokibart Phase 3 Result and Wins New KEYTRUDA Oncology Approvals

Regencell Bioscience Faces DOJ Investigation After May $20 Million Equity Raise and Heavy Losses

Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes

JNJ: Drug Pipeline Optimism Will Face Pressure From Medicare Pricing Rules

Corcept Therapeutics Ups 2026 Revenue Outlook on Early Lifyorli Uptake and Pipeline Progress

DT120 Hits Phase 3 Goals in Major Depression Pivotal Trial as Definium Eyes $500 Million Raise

Viatris Inc. to Report Q2, 2026 Results on Aug 06, 2026

Eli Lilly Surges Past Q1 Forecasts With Strong GLP-1 Demand and Raised 2026 Outlook

Teva Launches Ahzantive Biosimilar in Europe and Unveils Positive Austedo Clinical Data

Crinetics Pharmaceuticals, Inc. to Report Q2, 2026 Results on Aug 04, 2026

Pfizer Expands Cancer and Obesity Pipeline After $80 Billion in Recent Acquisitions

Liquidia Corporation(NasdaqCM:LQDA) dropped from Russell 3000E Growth Benchmark

Agomab Therapeutics NV Announces Design Of NOV-ERA Phase 2b Study With Ontunisertib In Fibrostenosing Crohn’s Disease

JAZZ: HER2 GEA Priority Review Will Support Future Oncology Leadership Narrative

Kardigan Surges After $400 Million Upsized Nasdaq IPO Debut